H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
KOIN Portland on MSN7h
Vancouver family launches son’s ashes into spaceA Vancouver family is sending their son on one final journey into the stars, where his ashes will eventually transform into a ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
Muscular Dystrophy (MD) is a genetic condition causing progressive muscle weakness and complications in vital organs. Early ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback